Nifedipine revisited: Extended-release formulations superior in patients with coronary artery disease, shows study
Coronary artery disease has been on a spiked rise owing to stressful lifestyles, coupled with unhealthy food choices and lack of regular exercise. The last decade has seen a boom in the morbidity and mortality rates associated with cardiovascular diseases, both young and old alike (1).
Cardiologists have since a long time now relied on calcium channel blockers as a first-line drug for such patients. Nifedipine, a well-documented drug for the therapy of unstable angina, acute myocardial infarction, hypertension, as well as in the protection of the myocardium at risk during open-heart surgery, has, since long, been widely accepted and prescribed by clinicians for patients with stable coronary artery diseases. (2,3)
The above article has been published by Medical Dialogues under the MD Brand Connect Initiative. For more details on Nifedipine, click here